Details for Patent: 8,545,832
✉ Email this page to a colleague
Which drugs does patent 8,545,832 protect, and when does it expire?
Patent 8,545,832 protects BRIXADI and is included in one NDA.
This patent has one hundred and fifteen patent family members in thirty-three countries.
Summary for Patent: 8,545,832
| Title: | Lipid depot formulations |
| Abstract: | The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament. |
| Inventor(s): | Thuresson Krister, Tiberg Fredrik, Johansson Markus, Harwigsson Ian, Joabsson Fredrik, Johnsson Markus |
| Assignee: | Camarus AB |
| Application Number: | US13537096 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 8,545,832
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-001 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-002 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-003 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION | ⤷ Sign Up | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-004 | May 23, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,545,832
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E401054 | ⤷ Sign Up | |||
| Austria | E462409 | ⤷ Sign Up | |||
| Austria | E501710 | ⤷ Sign Up | |||
| Australia | 2005249274 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
